Late Breaking Abstract - Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: a randomized, double-blind, cross-over trial
M. Lichtblau (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), J. Müller (Zürich, Switzerland), P. Appenzeller (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), L. Mayer (Zürich, Switzerland), M. Furian (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), E. Swenson (Seattle, United States), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
Source: International Congress 2022 – Treatment of pulmonary arterial hypertension
Session: Treatment of pulmonary arterial hypertension
Session type: Thematic Poster
Number: 2689
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Lichtblau (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), J. Müller (Zürich, Switzerland), P. Appenzeller (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), L. Mayer (Zürich, Switzerland), M. Furian (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), E. Swenson (Seattle, United States), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland). Late Breaking Abstract - Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: a randomized, double-blind, cross-over trial. 2689
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|